Sol-Gel Technologies Ltd. Ordinary Shares (SLGL)
- Headquarters
- United States
- Employees
- 28
- Market Cap
- $277M
About Sol-Gel Technologies Ltd. Ordinary Shares
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
SentiSense also tracks daily options readings for Sol-Gel Technologies Ltd. Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Sol-Gel Technologies Ltd. Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.